GTH

Genetron Health Reiterates Full Year 2021 Revenue Guidance

Retrieved on: 
Monday, January 10, 2022
RMB, SEC, MRD, GTH, Growth, Hepatocellular carcinoma, Molecular biology, Publication, Forward-looking statement, CRC, CEO, Private Securities Litigation Reform Act, Company, Fosun Pharma, Diagnosis, IVD, COVID-19, Phrase, GLOBE, AstraZeneca, Pharmaceutical industry

BEIJING, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reiterated its full year 2021 revenue guidance.

Key Points: 
  • BEIJING, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reiterated its full year 2021 revenue guidance.
  • The Company expects full year 2021 revenue to be around RMB 530 million, representing approximately 25% growth over the Companys full year 2020 revenue.
  • We are pleased with our accomplishments in 2021 amid a challenging operating environment that continues to be heavily impacted by the COVID-19 pandemic, said Mr. Sizhen Wang, co-founder and CEO of Genetron Health.
  • Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.

Genetron Health’s Social Contribution Campaign to Make Precision Medicine More Accessible

Retrieved on: 
Monday, December 13, 2021
Phrase, Forward-looking statement, Prognosis, Primary health care, Company, Workers Democratic Party, Radiation, Diagnosis, Hospital, Private Securities Litigation Reform Act, Chinese Peasants' and Workers' Democratic Party, Lung cancer, EGFR, AstraZeneca, GTH, Cancer, Entrepreneurship, NASDAQ, SEC, CEO, Research, Patient, Molecular biology, GLOBE, Classification, Sichuan University, Ministry, Precision medicine, Technology, Genetic testing, Non-small-cell lung carcinoma, Medical imaging, Pharmaceutical industry, NSCLC

As the sole corporate donor, Genetron Health will provide free genetic testing services (using its 8-gene lung cancer assay) for 10,000 Chinese lung cancer patients.

Key Points: 
  • As the sole corporate donor, Genetron Health will provide free genetic testing services (using its 8-gene lung cancer assay) for 10,000 Chinese lung cancer patients.
  • Meanwhile, identifying rare driver gene mutations is also crucial to the diagnosis and treatment of lung cancer.
  • This particular project will leverage 8-gene lung cancer assays and testing services provided by Genetron Health.
  • We hope that in the future, there will be more companies that are as enthusiastic about public welfare as Genetron Health is, and are committed to improving precision medicine accessibility.

Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in China

Retrieved on: 
Tuesday, November 30, 2021
Patient, Senior, CEO, Phrase, Time, Private Securities Litigation Reform Act, Forward-looking statement, Company, Partnership, Diagnosis, Recurrence, GTH, Cancer, IVD, SEC, Blood, Solution, Molecular biology, AstraZeneca, Nucleic acid thermodynamics, Program, NGS, MRD, Hope, Methylation, DNA, Mutation, GLOBE, Whole genome sequencing, NASDAQ, De novo, Pharmaceutical industry, Medical imaging

Under the agreement, the companies will jointly invest capital for this collaboration, and will work together to develop and validate the personalized, solid tumor MRD assays for cancer monitoring and recurrence in China.

Key Points: 
  • Under the agreement, the companies will jointly invest capital for this collaboration, and will work together to develop and validate the personalized, solid tumor MRD assays for cancer monitoring and recurrence in China.
  • For solid tumor clinical trials in China that incorporate the use of NGS-based personalized MRD tests, AstraZeneca plans to incorporate the aforementioned co-developed MRD test in China-specific studies, subject to fulfillment of individual study criteria.
  • Upon both companies' further agreement, the scope of the agreement may also be expanded to include IVD registration and commercialization.
  • Statements that are not historical facts, including statements about the Companys plans, strategies and timelines to develop personalized MRD tests for solid tumors in China with AstraZeneca R&D China, are forward-looking statements.

Genetron Health Reveals Two Cancer Research Study Results at the Association for Molecular Pathology 2021 Annual Meeting

Retrieved on: 
Tuesday, November 16, 2021
Bone marrow, Cancer, GTH, Industry, Private Securities Litigation Reform Act, Government, Immortalised cell line, Leadership, Infection, Education, Lymphatic system, NASDAQ, MRD, RNA, Classification, Committee, Phrase, MM, Working group, Research, Forward-looking statement, LOD, Health, Policy, Marie Cassidy, Association, Twitter, Multiple myeloma, Board, Company, GLOBE, AMPATH, Molecular biology, Board of directors, SEC, Limiting factor, Diagnosis, LOB, BCR, DNA, Patient, AMP, Biopsy, B-ALL, Medical imaging, Vaccine

FusionScan Plus provides an effective reference for clinical pathological classification and targeted therapy strategies by detecting gene mutations and fusions.

Key Points: 
  • FusionScan Plus provides an effective reference for clinical pathological classification and targeted therapy strategies by detecting gene mutations and fusions.
  • After hematological cancer treatment, patients bodies may sometimes not respond to treatment, or drug-resistant cancer cells may linger.
  • The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics.
  • Genetron Holdings Limited (Genetron Health or the Company) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.

Genetron Health to Participate in the 8th BioCentury-BayHelix China Healthcare Summit

Retrieved on: 
Monday, November 15, 2021
GTH, Private Securities Litigation Reform Act, Phrase, Forward-looking statement, Company, GLOBE, Molecular biology, SEC, Boot camp, Diagnosis

Genetron Health Chief Financial Officer, Evan Xu, will be a panelist in the Hands-On Bootcamp: Assessing the Capital Markets Situation in China and the U.S. discussion available on-demand for conference participants.

Key Points: 
  • Genetron Health Chief Financial Officer, Evan Xu, will be a panelist in the Hands-On Bootcamp: Assessing the Capital Markets Situation in China and the U.S. discussion available on-demand for conference participants.
  • This workshop will address key C-Suite questions and discuss strategies to reduce regulatory risk while meeting investor expectations for global competitiveness.
  • Genetron Holdings Limited (Genetron Health or the Company) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.
  • Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.

Genetron Health Announces Publication of Enhanced Variant Caller Performance Data in Briefings in Bioinformatics

Retrieved on: 
Monday, November 15, 2021
Systems biology, Adoption, Data, Cancer, GTH, Private Securities Litigation Reform Act, GIAB, Neoplasm, Education, Entrepreneurship, NASDAQ, Bayes, CEO, Prognosis, NGS, Phrase, Research, Forward-looking statement, Company, GLOBE, Molecular biology, SEC, UVC, Diagnosis, DNA, Patient, Lipid, Mobile phone, Medical imaging

UVC is a patent-protected algorithm developed by Genetron for use in the companys NGS products for optimization of the variant calling process.

Key Points: 
  • UVC is a patent-protected algorithm developed by Genetron for use in the companys NGS products for optimization of the variant calling process.
  • Key findings1 from the publication include:
    By utilizing extreme-case analysis to build statistical models, researchers found new principles to improve variant calling.
  • Continuing R&D to optimize our products and generating clinical data to drive adoption and utilization of our tests remains a top priority at Genetron, said Sizhen Wang, Co-Founder and CEO of Genetron Health.
  • We are very pleased with the findings in this publication and the execution from our bioinformatics team to drive growth initiatives.

Genetron Health Establishes Strategic Partnership with NeoGenomics to Drive Global Oncology Drug Research and Development

Retrieved on: 
Monday, November 8, 2021
Norwich Pharma Services, Genta (company), APJ, NeoGenomics, GTH, Cancer, Flow cytometry, CLIA, Diversified Pharmaceutical Services, NASDAQ, Technology, Information services, Oncology, Phrase, EMEA, Forward-looking statement, Marie Cassidy, Partnership, Company, GLOBE, Cdx, Molecular biology, Laboratory, Genetic testing, SEC, Diagnosis, CAP, Physician, Patient, Drug development, NEO, Pharmaceutical industry, Medical imaging

Genetron Health and NeoGenomics, Inc. will partner globally to provide select harmonized clinical trials, global translational research for pharmaceutical groups and technology platform providers that need a China arm for global or China focused trials.

Key Points: 
  • Genetron Health and NeoGenomics, Inc. will partner globally to provide select harmonized clinical trials, global translational research for pharmaceutical groups and technology platform providers that need a China arm for global or China focused trials.
  • Additionally, NeoGenomics will support Genetron Health on ex-China trials requiring US, APJ and/or EMEA based trials.
  • These assets will enable business partners to synchronize global clinical drug trials and companion diagnostics development.
  • Together, we will work to synchronize global oncology drug development, in order to accelerate market approval for new drugs and benefit patients around the world.

Genetron Health to Announce Third Quarter 2021 Financial Results and Host Investor Call on November 30, 2021

Retrieved on: 
Thursday, November 4, 2021
SEC, News, Diagnosis, Webcast, GTH, Private Securities Litigation Reform Act, Investor, Company, Phrase, Molecular biology, Forward-looking statement, Public relations

A replay of the webcast will be available for 30 days following the event.

Key Points: 
  • A replay of the webcast will be available for 30 days following the event.
  • Genetron Holdings Limited (Genetron Health or the Company) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.
  • Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.
  • Statements that are not historical facts, including statements about the Companys beliefs and expectations, are forward-looking statements.

Genetron Health’s Multi-Gene Mutation Detection Kit Onco PanScan™ Obtains CE Mark

Retrieved on: 
Thursday, November 4, 2021
European Society for Medical Oncology, Immunotherapy, Technology, Diagnosis, Gene, Cancer, Certification, Molecular biology, LDT, European Union, NGS, NCCN, IDH1, Patient, Private Securities Litigation Reform Act, GTH, World Health Organization, MSI, ESMO, SEC, Forward-looking statement, Marketing, Company, TMB, Phrase, CEO, CE, Union, Oncology, National Comprehensive Cancer Network, WHO, IVD, GLOBE, CE marking, Medical device

Onco PanScanis Genetrons comprehensive genomic profiling test, and is based on hybridization capture and next-generation sequencing (NGS) technology.

Key Points: 
  • Onco PanScanis Genetrons comprehensive genomic profiling test, and is based on hybridization capture and next-generation sequencing (NGS) technology.
  • Aside from Onco PanScan, the Companys TERT and IDH1 assays along with 8-Gene Lung Cancer Assay have all been approved in China and have received the CE Marks.
  • The CE mark stands for CONFORMITE EUROPEENNE, a security-certified mark, and is seen as a passport for manufacturers to open and enter the European market.
  • In the EU market, the CE mark is a compulsory certification mark, whether it is a product produced within the EU enterprise or a product produced in other countries.

Genetron Health Wins Second Prize of China’s National Science and Technology Progress Award for Contributions to Lung Cancer Precision Medicine Project

Retrieved on: 
Wednesday, November 3, 2021
EGFR, Mutation, Research, PIK3CA, MET, Diagnosis, NSCLC, Technology, Hospital, National Science Board, State Council, Gene, Guideline, Molecular biology, Crizotinib, Investment-specific technological progress, Organization, NCCN, BRAF, Patient, Private Securities Litigation Reform Act, Sichuan University, GTH, NMPA, RNA, SEC, ALK, Lists of science and technology awards, Forward-looking statement, Company, Phrase, Biomarker, CE, Mark (given name), Lung cancer, HER2, Non-small-cell lung carcinoma, ROS1, GLOBE, Central China, Gefitinib, CE marking, KRAS, DNA, Medical imaging, Pharmaceutical industry

Genetron Health stood out as the only award recipient that focused on precision oncology this year.

Key Points: 
  • Genetron Health stood out as the only award recipient that focused on precision oncology this year.
  • The National Science and Technological Progress Award is one of the five National Science and Technology Awards, established by the State Council in China.
  • Led by Professor Li Weimin from West China Hospital Sichuan University, the initiative received significant support from Genetron Health.
  • The project focused on tackling the issue of missed diagnosis in early-stage lung cancer and built a forecasting model based on imaging.